Could GLP-1 Drugs Be Slowing Biological Age?

A new randomised, placebo-controlled trial published in Nature Communications found that semaglutide slowed several validated markers of biological ageing, including a 9% slower pace of ageing on the DunedinPACE clock. The effect appeared independent of weight loss alone. It's early evidence, not proof that semaglutide extends lifespan.

For most people, GLP-1 medications like semaglutide are known for one thing: weight loss. But researchers are now asking a bigger question. Could these medications also be slowing down the biological ageing process itself?

A study published in Nature Communications in 2026 suggests they might.

Biological Age vs Chronological Age

Your chronological age is simply how many birthdays you've had. Your biological age reflects how well your cells, tissues and organs are actually functioning.

Two people can both be 50 years old. One might have the biology of a healthy 42-year-old. The other might resemble someone considerably older. That gap matters, because biological age tracks more closely with disease risk than the number on a birth certificate does.

Scientists estimate biological age using epigenetic clocks. These tools analyse patterns of DNA methylation, chemical marks on DNA that shift predictably as we age and correlate with disease risk and longevity.

Inside the Study

Researchers analysed blood samples from a 32-week clinical trial involving 84 adults with HIV-associated lipohypertrophy, a condition where excess fat builds up around the abdomen and organs. Participants received either weekly semaglutide or a placebo, in a randomised, double-blind design.

People living with HIV are a useful population for this kind of research because chronic inflammation, even when the virus itself is well controlled, tends to accelerate biological ageing. This made it possible to measure meaningful shifts in ageing biomarkers over a relatively short 32-week window.

The trial wasn't originally designed to study ageing. Its main goal was measuring change in visceral fat. The epigenetic ageing analysis was a planned follow-up look at the data, using 17 different DNA methylation clocks spanning three generations of the technology.

What Did the Researchers Find?

Compared with placebo, participants receiving semaglutide showed measurable improvements across multiple independent epigenetic clocks:

• Roughly 9% slower pace of biological ageing on the DunedinPACE clock
• A meaningfully lower annual increase in PCGrimAge, a clock associated with mortality risk
• Improvements on PhenoAge, GrimAge, and several other second and third generation clocks
• Ageing signals improved across markers linked to inflammation, cardiovascular health, brain health, liver function, kidney function and metabolic health

This is one of the first randomised human trials to show that a GLP-1 receptor agonist may influence recognised biomarkers of biological ageing, rather than just weight or blood sugar.

Why Might This Happen?

Interestingly, the researchers don't believe the effect is simply a byproduct of weight loss. Semaglutide appears to influence several of the core biological processes thought to drive ageing itself, including:

• Reducing chronic inflammation
• Improving insulin sensitivity
• Decreasing excess visceral and ectopic fat
• Supporting mitochondrial function
• Lowering oxidative stress
• Improving overall metabolic health

These pathways sit at the centre of most current thinking on why we age, which is why researchers describe semaglutide's potential role here as gerotherapeutic, meaning it may act on ageing biology directly rather than treating individual diseases one at a time.

Does This Mean GLP-1 Drugs Are Anti-Ageing Medications?

Not yet, and it's worth being precise about what the study does and doesn't show.

The trial was conducted in adults living with HIV who had abnormal fat distribution, so the same magnitude of benefit can't be assumed in healthy adults without HIV. It measured biological ageing biomarkers, not lifespan or long-term healthspan outcomes. And it was a post-hoc analysis of a trial designed for a different primary purpose, which means the ageing findings, while promising, weren't the study's original hypothesis.

In short, the results are encouraging but not conclusive. Larger trials in broader populations, designed specifically to study ageing outcomes, will be needed before GLP-1 drugs can be considered established gerotherapeutics.

What Does This Mean for Longevity Science?

Perhaps the most interesting shift here isn't the specific percentage on a specific clock. It's how researchers are starting to think about GLP-1 drugs.

Instead of viewing them purely as weight loss tools, scientists are increasingly looking at them as agents that may influence multiple hallmarks of ageing at once, by lowering chronic inflammation and improving the body's broader metabolic environment.

That reflects a wider shift happening across longevity medicine. Rather than treating age-related diseases individually as they appear, researchers are moving toward targeting the shared biological processes that drive many of those conditions in the first place.

For now, this study is a signal worth paying attention to, not a verdict. The next few years of research will tell us how far that signal actually goes.

Where Does This Leave the Rest of Us?

Not everyone is a candidate for GLP-1 medication, and it isn't the only lever for supporting healthy ageing. The same biological pathways this study points to, inflammation, insulin sensitivity, mitochondrial function and oxidative stress, are also influenced by daily habits: sleep, movement, nutrition and targeted nutritional support. At [STMNA Bioactives], our Healthspan range is built around supporting those same underlying processes, so your daily habits and your biology are working in the same direction. [Explore the Healthspan range] to see how.

FAQ

Do GLP-1 drugs like semaglutide slow biological aging?

A 2026 randomised, placebo-controlled trial found semaglutide slowed several epigenetic markers of biological ageing, including a 9% slower pace of ageing on the DunedinPACE clock. This is early evidence from one trial, not a confirmed anti-ageing effect.

What is biological age compared to chronological age?

Chronological age is how many years you've been alive. Biological age reflects how well your cells and organs are actually functioning, and is estimated using epigenetic clocks that analyse DNA methylation patterns.

Was this study done in healthy adults?

No. The trial involved adults living with HIV who had HIV-associated lipohypertrophy. Results may not translate directly to the general population, and further research is needed.

Does semaglutide's effect on ageing come from weight loss alone?

Researchers believe the effect goes beyond weight loss, pointing to reduced inflammation, improved insulin sensitivity, better mitochondrial function and lower oxidative stress as likely contributing pathways.

Does this mean semaglutide extends lifespan?

No. The study measured biological ageing biomarkers, not lifespan or long-term health outcomes. Larger trials are needed before any lifespan claims can be made.

GLP-1 drugs biological aging, semaglutide biological age, epigenetic clock GLP-1, does semaglutide slow aging, semaglutide longevity study, DunedinPACE semaglutide, biological age vs chronological age, semaglutide inflammation, GLP-1 anti-aging, gerotherapeutics, semaglutide healthspan, longevity science research